title: [Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections].
abstract: OBJECTIVE
  The authors had for aim to define the threshold of nephrotoxicity before switching to other antifungal treatment in hematological patients treated by conventional amphotericin B (AmB) as an empiric antifungal treatment.
  
  
  METHODS
  A prospective randomised multicenter study was made on 32 neutropenic hematological patients receiving conventional AmB for empirical antifungal treatment. The patients were randomised after a greater than or equal to 30% increase of serum creatinine (sCr). Patients in the early-switch group received liposomal AmB just after randomisation and patients in the late-switch group received liposomal AmB only when serum creatinine increase was greater or equal to 100% or sCr reached 170mumol/L.
  
  
  RESULTS
  Thirty-one patients were analysed: 16 patients in the early-switch group and 15 patients in the late-switch group (seven switched to liposomal AmB and eight continued conventional AmB treatment). The mean age of patients was 48 years and 68% were men. The most frequent underlying haematological malignancy was acute leukemia (94%). In the late-switch group, the degradation of renal function continued after randomisation contrary to the early-switch group: median variations of calculated sCr clearance in early- and late-switch groups were -16.8 and -1.5%, respectively (P=0.03). Moreover, an early switch was cost-effective with a sCr lower duration of hospitalisation in comparison with a late switch.
  
  
  CONCLUSIONS
  This randomised trial suggests that an early switch to Liposomal AmB improves and preserves renal function in comparison with a late switch.
authors.affiliation: Service hématologie, hôpital St-Antoine, 184, rue du Faubourg-St-Antoine, 75571 Paris cedex 12, France. francoise.isnard@sat.aphp.fr
authors.forename: F
authors.initials: F
authors.lastname: Isnard
authors.forename: P
authors.initials: P
authors.lastname: Tilleul
authors.forename: J-P
authors.initials: JP
authors.lastname: Laporte
authors.forename: P
authors.initials: P
authors.lastname: Chevallier
authors.forename: A
authors.initials: A
authors.lastname: Pigneux
authors.forename: A
authors.initials: A
authors.lastname: Lafuma
authors.forename: F
authors.initials: F
authors.lastname: Monchecourt
authors.forename: L
authors.initials: L
authors.lastname: Mahi
authors.forename: G
authors.initials: G
authors.lastname: Deray
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D003404:Creatinine / Q000097:blood; D004342:Drug Hypersensitivity; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D007677:Kidney Function Tests; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D000935:Antifungal Agents; D008081:Liposomes; D000666:Amphotericin B; D003404:Creatinine